LBRX Stock Summary and Trading Ideas (LB Pharmaceuticals | NASDAQ:LBRX)

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

LB Pharmaceuticals trades on the NASDAQ stock market under the symbol LBRX.

As of October 5, 2026, LBRX stock price declined to $34.62 with 475,832 million shares trading.

LBRX has a beta of 1.43, meaning it tends to be more sensitive to market movements. LBRX has a correlation of 0.11 to the broad based SPY ETF.

LBRX has a market cap of $1.12 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that LBRX belongs to (by Net Assets): VTI, IWM, VXF, XPH, VTWO.

LBRX has outperformed the market in the last year with a return of +123.9%, while the SPY ETF gained +16.9%. However, in the most recent history, LBRX shares have underperformed the stock market with its stock returning +3.6% in the last 3 month period and -18.5% for the last 2 week period, while SPY has returned +4.3% and +1.7%, respectively.

LBRX support price is $35.70 and resistance is $38.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LBRX shares will trade within this expected range on the day.